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A fully validated UHPLC method for the identification and quantification of pharmaceutical 13 
preparations, containing paracetamol and/or acetyl salicylic acid, combined with anti-14 
histaminics (phenylephrine, pheniramine maleate, diphenhydramine, promethazine) and/or 15 
other additives as quinine sulphate, caffeine or codein phosphate, was developed. The 16 
proposed method uses a Waters Acquity BEH C18 column (2 x 100mm 1.7µm) with a 17 
gradient using an ammonium acetate buffer pH 4.0 as aqueous phase and methanol as organic 18 
modifier. The obtained method was fully validated based on its measurement uncertainty 19 
(accuracy profile) and robustness tests. Calibration lines for all components were linear within 20 
the studied ranges. The relative bias and the relative standard deviations for all components 21 
were respectively smaller than 1.5% and 2%, the β-expectation tolerance limits did not exceed 22 
the acceptance limits of 10% and the relative expanded uncertainties were smaller than 5% for 23 
all of the considered components.   24 
 2 
A UHPLC method was obtained for the identification and quantification of these kind of 25 
pharmaceutical preparations, which will significantly reduce analysis times and workload for 26 
the laboratories charged with the quality control of these preparations. 27 
 28 
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1. Introduction  41 
 42 
Pharmaceutical preparations containing paracetamol and/or non-steroidal anti-inflammatory 43 
drugs (NSAID) as acetyl salicylic acid or ibuprofen, are frequently used. In Belgium these 44 
preparations are often made in-house by the pharmacist. Often they are combined with anti-45 
histaminics as diphenhydramin and pheniramin maleate and some other active components as 46 
caffeine and codein. The antihistaminics are added in formulations for the symptomatic 47 
treatment of the flue and flue-like illnesses, like a common cold. The paracetamol and/or the 48 
NSAID treats the fever and possible pains, while the anti-histaminic relieves the symptoms of 49 
nasal congestion. Caffeine and codein are added for their synergic activity with paracetamol 50 
and NSAID’s. Therefore a minimal dose of 30 mg has to be present in the formulation.  51 
 52 
Because of the extended use of this kind of preparations the authorities need to check the 53 
quality of these products. The European Pharmacopeia [1] describes only analytical methods 54 
for bulk products while the United States Pharmacopeia [2] describes the analysis of some 55 
preparations, but limiting itself to preparations containing only an NSAID or the combination 56 
with caffeine or codein. Due to the fact that these preparations are prepared in-house with or 57 
without recipe of a medical doctor, a lot of variation exists as well in composition as in the 58 
doses of the different compounds. Due to the variation in the formulations the laboratories 59 
charged with the analysis have a series of methods that were developed for the analysis of 60 
such preparations in the course of time. 61 
In literature several methods are described for the analysis of mixtures of NSAID’s and 62 
additives. Most methods describe classical HPLC methods with simple UV or DAD detection. 63 
Both normal phase [3] as reversed phase [4-13] methods can be found. Further methods can 64 
be found using LC-MS [14,15], capillary electrophoresis [16-21] and micellar electrokinetic 65 
 4 
chromatography [17,20,22]. Other methods like fluorimetric determinations [23], sequential 66 
injection analysis [24] and thin layer chromatography [25] are also available. 67 
The development of a generic applicable method allowing the analysis of a major part of the 68 
formulations with the same system would save resources and time.  69 
This paper describes a validated chromatographic method capable of analysing at least ten of 70 
the frequently occurring components in the concerned formulations made by pharmacists in 71 
Belgium. In first instance the development was focused on HPLC, but soon it was seen that 72 
analysis times would be too long to be practical. Therefore it was decided to concentrate on 73 
UHPLC, allowing shorter analysis times and an important saving of organic solvents.  74 
In a first step a method was developed to separate ten compounds, selected based on the in 75 
house database containing all pharmaceutical formulations analysed in our lab in the past. In a 76 
second part the method was validated according to the requirements of the ISO 17025 77 
guideline [26]. The robustness of the method was tested using a full factorial design following 78 
the method proposed by Massart et al. [27] with as factors the pH, the flow and the 79 
temperature. 80 
 81 
2. Methods and materials 82 
2.1. Chemicals and reagents 83 
The reference standards for Paracetamol (batch 08J09-B02-230199), Salicylic acid (batch 84 
08H29-B01-229453) and Quinine sulphate (batch 09B12-B05-232890) were purchased from 85 
Fagron (Waregem, Belgium). Acetyl Salicylic Acid (batch 04J04GO) and Phenylephrine.HCl 86 
(batch 08C26-B04) were purchased from BUFA (Uitgeest, The Netherlands), Caffeine (batch 87 
06D11-B01-215309) and Diphenhydramine.HCl (batch 07A22-B10-219304) from Certa 88 
(Braine-L’Alleud, Belgium), Pheniramine maleate (batch 068K1128) and Promethazine.HCl 89 
 5 
(batch 097K1276) from Sigma-Aldrich (St. Louis, USA) and Codein Phosphate Hemihydrate 90 
(batch 06C15/V24735) from Conforma (Destelbergen, Belgium).  91 
 92 
For the preparation of the mobile phases ammonium Acetate and ammonium solution were 93 
purchased from Merck (Darmstadt, Germany), formic acid from VWR prolabo (Fontenay-94 
Sous-Bois, France) and MeOH and acetonitril, both HPLC-grade, from Biosolve 95 
(Valkenswaard, The Netherlands).  96 
 97 
2.2. Instrumental conditions 98 
Method development and validation was performed on an Acquity UPLCTM system (Waters, 99 
Milford, USA). The system consisted of a binary solvent manager, a sample manager and a 100 
photo diode array detector. The output signal was monitored and processed using the Waters 101 
Empower2 software. 102 
 103 
The initial screening tests were performed using combinations of two stationary phases, an 104 
Acquity BEH C18 column 2.1 x 100mm 1.7µm (Waters) and a Grace Vision HTTM C18-P 2 x 105 
100mm 1.5µm (Grace Davision Discovery Sciences, Lokeren, Belgium) two organic buffers, 106 
an ammonium formate buffer 0.025M of pH 3 and an ammonium acetate buffer 0.025 M of 107 
pH 4, and two organic modifiers acetonitril and methanol. The gradient used starts at 98% 108 
buffer and 2% organic modifier, going to a plateau of 30% buffer in 8 minutes. These 109 
conditions are held for 2 minutes before returning to the initial conditions. The gradient was 110 
linear and the flow was 0.50 ml/min. The injection volume was 2µl, the column temperature 111 
50°C and the detection wavelength 254 nm. This wavelength was selected since all of the 112 
components showed enough sensitivity at 254 nm. 113 
 6 
Method optimisation and validation were performed on the Acquity BEH C18 column under 114 
gradient conditions using a mobile phase composed of a 0.025 M ammonium acetate buffer of 115 
pH 4 and methanol. 116 
  117 
2.3. Sample preparation 118 
2.3.1. Preparation of standards 119 
Calibration standards were prepared starting from separated stock solutions for each of the ten 120 
components. The respective stock solutions contained 5 mg/ml paracetamol, 5 mg/ml 121 
acetylsalicylic acid, 0.2 mg/ml promethazine, 0.2 mg/ml phenylephrine.HCl, 0.2 mg/ml 122 
salicylic acid, 0.3 mg/ml pheniramine maleate, 0.3 mg/ml diphenhydramin.HCl, 1.2 mg/ml 123 
codeine phosphate hemihydrate, 1.2 mg/ml caffeine and 1 mg/ml quinine hydrochloride.  124 
Starting from these solutions standards were prepared by making dilutions of respectively 1.0, 125 
2.5, 5.0, 7.5 and 10.0 ml in 50ml. All solutions were prepared in methanol containing 1% of 126 
formic acid to ensure the stability of acetyl salicylic acid and promethazine.HCl in solution. 127 
 128 
2.3.2. Preparation of samples 129 
In order to validate the method following, the “total error” approach, blank spiked samples 130 
were prepared starting from stock solutions with the same concentrations as the ones used for 131 
the preparation of the standards. Stock solutions for sample preparation were prepared 132 
separately from the ones used for the standards. For the preparation of the validation samples 133 
a blank matrix consisting of lactose was used. 100 mg of the matrix was spiked with the stock 134 
solutions and brought to volume with methanol containing 1% of formic acid. The samples 135 
were brought in the ultrason bath for 10 minutes. Starting from the stock solutions three 136 
samples were prepared with different concentration levels. The concentration levels of the 137 
different components were chosen in function of the concentrations occurring in 138 
 7 
pharmaceutical preparations previously analysed at our laboratory. Attention was paid to the 139 
fact that in all three samples the different components were present in concentrations showing 140 
the same proportions as the solutions obtained with samples from practice. Table 1 shows the 141 
concentration levels chosen for each of the analytes. 142 
 143 
As example a real sample containing 300 mg acetyl salicylic acid, 250 mg paracetamol, 20 144 
mg caffeine, 10 mg codeine phosphate and 20 mg of diphenhydramine was analysed. 20 145 
capsules were emptied and homogenised. A quantity of powder corresponding to 60 mg of 146 
acetyl salicylic acid was brought in methanol containing 1% of formic acid and put on 147 
ultrason for 10 minutes. A clear solution was obtained and the solution was brought to 100 ml 148 
with methanol containing 1% of formic acid. 149 
  150 
2.4. Experimental design 151 
The robustness testing of the method was performed using experimental design. A three-152 
factor three-level full factorial design was applied [27]. The experiments were randomly 153 
performed in triple and the effects of the different factors were interpreted using regression. A 154 
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where b0 represents the intercept, bi and bij the regression coefficients and xi the factors tested. 157 
The significance of the regression coefficients is a value for the significance of the effects of 158 
the different factors on the response. The regression coefficients of the products of two factors 159 
represent the significance of their interaction effects [27]. 160 
 161 
2.5. Method validation 162 
 8 
The method validation was performed in accordance with the requirements of the ISO17025 163 
guideline using the total error approach [26, 28-30].  164 
Therefore the spiked blank samples prepared in section 2.3.2 were prepared in triple and 165 
analysed for three consecutive days. The concentrations of the spiked samples were back-166 
calculated using the calibration lines, prepared as described in section 2.3.1., to determine the 167 
linearity between theoretical and measured concentrations, the mean relative bias, the 168 
repeatability, the intermediate precision and the β-expectation tolerance or total error intervals 169 
at the 5% level. 170 
 171 
2.6. Statistics 172 
 173 
The statistical analysis was performed using Statgraphics Plus 5.1 (STSC Inc.,Rockville, MD, 174 
USA) and Microsoft Excell 2003. Visualisation of the response surfaces was executed using 175 
Matlab version 7.9 R2009b (The Mathworks Inc., Matick, MA). 176 
 177 
3. Results 178 
 179 
3.1. Selection of the system to be optimised 180 
The initial screening tests were performed as described in section 2.2.  181 
Visual inspection of the obtained chromatograms led to the conclusion that the best initial 182 
separation was obtained using a mobile phase of methanol with the ammonium acetate buffer 183 
and the Acquity BEH C18 column. This method was used as starting point for further method 184 
optimisation. Figure 1 shows the corresponding chromatogram. 185 
 186 
3.2. Optimisation of the method 187 
 9 
From figure 1 it can be seen that phenylephrine is eluted with the void volume and that the 188 
separation between acetyl salicylic acid and caffeine is not optimal. Therefore the initial 189 
gradient was adapted by lowering the percentage of aqueous phase in the initial conditions, 190 
keeping the initial conditions for one minute and going to a plateau of 50/50 buffer/methanol 191 
in 8 minutes. These adaptations to the gradient let to a good separation (resolution > 1.5) for 192 
all ten components as well as to an improvement in peak symmetry (0.80-1.30). In principle 193 
the run time of the method could still be reduced, though we chose to keep it at 11 minutes in 194 
order to obtain a more general applicable method. Keeping a longer run time and higher 195 
resolutions improves the opportunity that a component present in a preparation that was not 196 
taken into account during the method development, can be detected and quantified with the 197 
same method. 198 
The final gradient starts at 95% ammonium acetate buffer pH 4 and 5% methanol. The initial 199 
conditions are kept for one minute, before going to a plateau of 50% buffer and 50% 200 
methanol in nine minutes. The plateau is maintained for two minutes before returning to the 201 
initial conditions. The gradient was linear and the flow was 0.50 ml/min. Figure 2a the 202 
corresponding chromatogram.  203 
As example figure 2b shows the chromatogram obtained for the real commercial sample 204 
described in section 2.3.2. 205 
This method was validated following the ISO 17025 requirements in order to implement it in 206 
the routine analysis of these combined pharmaceutical preparations. 207 
 208 
3.3. Validation 209 
3.3.1. Selectivity 210 
 10 
The selectivity of detection was ensured by determining the retention time of each component 211 
separately and by monitoring the UV-spectra of the different components during the different 212 
analyses.  213 
 214 
3.3.2. Linearity of the calibration lines 215 
For all of the ten components four calibration standards were prepared in order to evaluate the 216 
relationship between the area under the curve and the concentration. The linearity of the 217 
relationship was evaluated for each of the components in a concentration range, covering the 218 
normal range of concentrations obtained when analyzing pharmaceutical preparations.  219 
The calibration curves were obtained using ordinary least-square linear regression and the 220 
linearity was confirmed with the R² values and a quality coefficient [31]. Table 2 summarizes 221 
for the ten components the concentration ranges of the calibration curves, the R² values and 222 
the quality coefficients. From this table it can clearly been concluded that the calibration 223 
curves for all components are linear within the chosen concentration ranges. 224 
 225 
3.3.3. Trueness, precision, accuracy and uncertainty assessment 226 
A statistical approach based on the “total error” profiles was applied to validate the method. 227 
As explained in section 2.3.2 spiked blank samples were prepared at three concentration 228 
levels. Table 3 gives the exact concentrations of the 3 levels for each of the components. 229 
Every sample was prepared in triple and analysed for three consecutive days.  230 
The concentrations of the spiked samples were back-calculated using the calibration lines, 231 
prepared as described in section 2.3.1., to determine the linearity between theoretical and 232 
measured concentrations, the mean relative bias, the repeatability, the intermediate precision 233 
and the β-expectation tolerance or total error intervals at the 5% level. All results are shown in 234 
table 4. 235 
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The relationship between the theoretical and the calculated concentrations for each of the ten 236 
components is clearly linear with R²-values from 0.9997 to 1.000. 237 
Trueness refers to the closeness of agreement between the average of the obtained values and 238 
the known exact concentration of the spiked samples and is a measure for the systematic 239 
errors of the method [30,32]. It is expressed in terms of relative bias.  From table 4 it can be 240 
concluded that the trueness for all components is acceptable since the relative bias is always 241 
smaller than 1,5%.  242 
The precision is a measure for the relative errors of the method and is expressed as the relative 243 
standard deviations (RSD) for repeatability and intermediate precision. From table 4 it can be 244 
seen that an acceptable precision is obtained for all components. The maximal RSD is 245 
obtained for phenylephrine and is 1.995%. 246 
Accuracy takes into account the total error of the test results and is represented by the β-247 
expectation tolerance intervals. The acceptance limits for the bias were set at 10 %. This is 248 
based on the fact that the general acceptance limits for the content of pharmaceutical 249 
preparations, made by a pharmacist, are from 90 to 110%. As shown in table 4 and figure 3 250 
the relative β-expectation tolerance intervals did not exceed the acceptance limits, which 251 
means that each future measurement of unknown samples will be included in the tolerance 252 
limits for the relative bias at the 10% level.  253 
The uncertainty represents the dispersion of the values that could reasonably be attributed to 254 
the analyte. The expanded uncertainty represents an interval around the results where the 255 
unknown true value can be observed with a confidence level of 95%. The relative expanded 256 
uncertainties (%) are obtained by dividing the corresponding expanded uncertainties with the 257 
corresponding concentrations. Results are shown in table 4. Since all uncertainties are below 258 
5% percent the method is considered to have acceptable uncertainties for all components. 259 
 260 
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3.3.4. Limits of detection and quantification 261 
The limits of detection and quantification of the method were calculated based on the standard 262 
deviation of the analysis of a blank and the sensitivity of the method [27]. 263 
A blank was analysed 10 times and the standard deviation of the signal at the retention time of 264 
each of the components was calculated. The limit of detection was calculated as three times 265 
the standard deviation of the blank divided by the sensitivity, equal to the slope of the 266 
calibration curve. The quantification limit was calculated as ten times the standard deviation 267 
of the blank divided by the sensitivity. The detection and quantification limits for all ten 268 
components are listed in table 5. 269 
 270 
3.3.5. Recovery 271 
The absolute recoveries of all ten components were determined at the three concentration 272 
levels used to construct the accuracy profile. The recoveries were determined by analysing 273 
spiked blank samples and calculating their concentrations using calibration lines in analogy 274 
with what was done for the accuracy profile. Table 6 summarizes the mean recoveries 275 
obtained for all ten components for each concentration level. All recoveries are within 276 
acceptable limits, indicating that the method is suited for the analysis of these active 277 
substances in pharmaceutical preparations. 278 
 279 
3.3.6. Robustness 280 
Robustness is a measure for the influence of small changes in the analytical 281 
procedure/parameters on the measured response.  282 
The test was performed by a 3-factor 3-level full factorial design, with the flow, the column 283 
temperature and the pH of the ammonium acetate buffer as factors and the resolution between 284 
caffeine and acetyl salicylic acid (critical pair) as response. The different levels were chosen 285 
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based on the errors which are common during such an analysis. Table 7 shows the 286 
experimental design performed and the corresponding resolutions obtained. All experiments 287 
were performed in random order. 288 
The effects of the different factors were calculated and their significance at the 5% level was 289 
tested by ANOVA analysis. Table 8 shows the calculated effects of the different factors as 290 
well as their interaction effects, with their standard errors, a measure for the sampling error. 291 
Figure 4 shows the standardized Pareto chart and figure 5a-c shows the response surfaces 292 
obtained with the regression methods. 293 
From the ANOVA analysis it could be seen that the regression is significant with an R2 of 294 
99.99%. From figure 4 and 5 and from the ANOVA table shown in Table 9 it could be seen 295 
that the temperature and the flow have a small significant effect on the resolution between 296 
caffeine and acetyl salicylic acid. The pH has a strong effect on the resolution between those 297 
two components. The effects of the temperature and the flow could be explained by the fact 298 
that UHPLC works with very high pressure. Little changes in temperature and flow cause an 299 
important change in the pressure, which influences retention and resolution. The strong effect 300 
of the pH on the resolution of the critical pair can be explained by the fact that pH 4.0 is close 301 
to the pKa value of acetyl salicylic acid. Comparing the different chromatograms obtained 302 
under the different conditions revealed that the retention time of acetyl salicylic acid changes 303 
strongly in function of the pH, while the shifts in retention times of the other components are 304 
less significant.  305 
Eventhough it was statistically proven that the pH, the temperature and the flow have 306 
significant effects on the resolution of the critical pair, this does not influence the quality of 307 
the method since the resolution of the critical pair stays always higher than 1.5 (Table 7). The 308 
method can be considered as suited for purpose. 309 
 310 
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4. Conclusions 311 
An Ultra Fast Liquid Chromatographic method was developed and validated for the 312 
qualitative and quantitative analysis of pharmaceutical preparations containing a series of 313 
non-steroidal anti-inflammatory drugs in combination with anti-histaminics and/or caffeine 314 
and codein phosphate. The validation was performed following the ISO17025 requirements 315 
and proved that the method was suited for purpose and can be used in the routine analysis of 316 
these pharmaceutical preparations. 317 
The method is a gradient method, using a 0.025 M ammonium acetate buffer of pH 4.0 as 318 
aqueous phase and methanol as organic phase. The gradient starts at a percentage of 95% of 319 
the buffer solution and comes to a plateau of 50% buffer at 9 minutes. The flow rate is 0.5 320 
ml/min and the detection wavelength 254 nm. 321 
The method was applied in the analysis of routine samples at our lab and showed a good 322 
performance. Depending on the composition of the sample the gradient could even be 323 
shortened in order to gain time and solvents. When the composition allowed it the method 324 
was also used in our laboratory to dose preparations containing ibuprofen, chlorphenamine 325 
maleate, metoclopramide, etc… , broadening the applicability of the method to preparations 326 
composed of other combination of non-steroidal anti-inflammatory drugs and anti-327 
histaminics. When using the method for other molecules as described in this paper, one 328 
should always check the method for the APIs in the preparation first. 329 
The fact to have a general applicable method that allows the analysis of the majority of the 330 
NSAID pharmaceutical preparations in a run time of twelve minutes represents a significant 331 
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Figure 1: Chromatogram obtained with the selected method from the initial screening. 
Figure 2: (a) Chromatogram obtained with the optimized gradient conditions. (b) Chromatogram obtained with a real commercial sample 
Figure 3: Accuracy profile of the ten components. The plain line is the relative bias, the dashed lines are the β-expectation tolerance limits, the 
bold plain line are the acceptance limits (10%) and the dots represent the relative back-calculated concentrations, plotted with respect to their 
targeted concentration. 
Figure 4: standardized Pareto chart for the resolution between caffeine and acetyl salicylic acid. 
Figure 5: (a) response surface for the effect of the pH and the temperature on the resolution of caffeine and acetyl salicylic acid; (b) response 
























































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































Figure 4 15 




















Figure 5b 20 
 29 





























Level 1 0.04 0.5 0.04 0.12 0.12 0.5 0.06 0.1 0.06 0.02 
Level 2 0.03 0.3 0.03 0.09 0.09 0.2 0.042 0.08 0.042 0.015 
Level 3 0.02 0.2 0.02 0.06 0.06 0.1 0.03 0.06 0.03 0.01 
  22 
 30 
Table 2:  summary of the quality of the calibration curves for the different components 23 
Component Concentration range R² value Quality Coefficient 
Phenylephrine.HCl 0.008 - 0.8 mg/ml 0.9999 0.521 % 
Paracetamol 0.1 – 1.0 mg/ml 0.9997 0.120 % 
Salicylic acid 0.008 - 0.8 mg/ml 0.9998 1.118 % 
Codeine Phosphate 0.024 – 0.24 mg/ml 0.9998 1.650 % 
Caffein 0.024 – 0.24 mg/ml 0.9998 1.546% 
Acetyl Salicylic acid 0.1 – 1.0 mg/ml 0.9997 0.170 % 
Pheniramine Maleate 0.012 – 0.12 mg/ml 1.0000 0.710 % 
Quinine sulphate 0.02 – 0.20 mg/ml 0.9999 1.630 % 
Diphenhydramine.HCl 0.012 – 0.12 mg/ml 1.0000 0.984 % 
Promethazine.HCl 0.004 – 0.04 mg/ml 0.9997 0.185 % 
 31 





























Level 1 0.0394 0.495 0.0408 0.120 0.123 0.500 0.0610 0.101 0.0578 0.0215 
Level 2 0.0296 0.297 0.0306 0.090 0.0926 0.200 0.0427 0.0805 0.0405 0.0161 
Level 3 0.0197 0.198 0.0204 0.060 0.0617 0.100 0.0305 0.0604 0.0202 0.0108 
 32 
Table 4: Trueness, precision, accuracy and uncertainty 25 
 








sulphate diphenhydramine.HCl Promethazine.HCl 
Trueness 
           
 1 -1,19 0,89 1,03 -0,86 0,06 0,85 0,2 0,59 1,48 0,53 
Relative bias (%) 2 -0,85 0,85 0,96 -1,17 0,1 0,39 0,13 0,3 0,60 0,46 
 3 0,93 -0,33 0,67 -0,55 0,36 -0,18 0,13 0,61 0,77 0,26 
Intra-assay precision 
           
 1 1,64 0,72 1,13 0,18 1,65 0,87 0,92 1,72 1,57 1,22 
Repeatability (RSD %) 2 1,88 0,68 1,37 0,37 0,49 0,47 0,86 0,86 1,24 0,91 
 3 2,00 0,21 0,63 0,73 0,69 0,29 0,26 0,29 1,93 1,04 
Between-assay precision 
           
 1 1,64 0,72 1,13 0,47 1,65 0,87 0,92 1,72 1,57 1,22 
Intermediate precision (RSD %) 2 1,88 0,92 1,37 0,47 0,70 1,01 0,86 0,86 1,74 0,91 
 3 2,00 1,22 0,77 0,78 0,78 1,45 0,72 0,68 1,93 1,24 
Accuracy 
           
 1 [-6,05;3,68] [-1,30;3,08] [-2,41;4,46] [-3,14;1,41] [-4,89;5,01] [-1.33;3.03] [-2,59;2,98] [-4,62;5,79] [-2,49;5,45] [-3,15;4,21] 
β-expectation tolerance limits (%) 2 [-6.41;4.78] [-2,43;4,13] [-3,19;5,11] [-2,48;0,13] [-2,39;2,58] [-4.56;5.34] [-2,47;2,72] [-2,30;2,89] [-4,76;5,96] [-2,27;3,19] 
 3 [-5.54;6.48] [-6.36;5.70] [-2,04;3,38] [-2,58;1,49] [-2,01;2,74] [-7.37;7.01] [-3,40;3,66] [-2,73;3,95] [-4,07;5,96] [-4,11;4,37] 
Uncertainty 
           
 1 3,50 2,54 2,48 1,06 3,57 1,84 2,01 3,74 3,36 2,65 
Relative expanded uncertainty 
(%) 2 4,03 2,68 2,99 1,01 1,56 2.30 1,87 1,87 3,86 1,97 
 3 4,33 2,80 1,70 1,66 1,71 3.34 1,64 1,55 4,10 2,74 
 26 
 33 
Table 5: detection and quantification limits. 27 
 28 
 LOD (µg/ml) LOQ (µg/ml) 
Phenylephrine.HCl 0.34 1.14 
Paracetamol 0.016 0.054 
Salicylic Acid 0.41 1.37 
Codein Phosphate 0.032 0.11 
Caffein 0.095 0.32 
Acetyl Salicylic Acid 0.093 0.31 
Pheniramin Maleate 0.020 0.068 
Quinine sulphate 0.017 0.055 
Diphenhydramin.HCl 0.22 0.73 
Promethazine.HCl 0.084 0.28 
 34 
 29 




















Level 1 97.87 % 100.24 % 99.18 % 100.05 % 98.30 % 100.43 % 100.58 % 100.58 % 101.25 % 101.09 % 
Level 2 99.60 % 99.64 % 98.87 % 100.10 % 98.34 % 99.24 % 100.78 % 100.44 % 101.08 % 100.86 % 
Level 3 100.94 % 97.93 % 97.58 % 100.72 % 99.45 % 97.24 % 101.20 % 100.91 % 101.38 % 100.65 % 
 35 
Table 7: 3-factor 3-level full factorial design for robustness testing 31 
Nr. experiment Flow (ml/min) Temperature 
(°C) 
pH Resolution for 
the critical pair 
1 0.49 49 3.9 7.38 
2 0.50 49 3.9 7.26 
3 0.51 49 3.9 7.19 
4 0.49 50 3.9 7.27 
5 0.50 50 3.9 7.24 
6 0.51 50 3.9 7.14 
7 0.49 51 3.9 7.25 
8 0.50 51 3.9 7.20 
9 0.51 51 3.9 7.10 
10 0.49 49 4.0 4.00 
11 0.50 49 4.0 3.92 
12 0.51 49 4.0 3.81 
13 0.49 50 4.0 3.95 
14 0.50 50 4.0 3.86 
15 0.51 50 4.0 3.78 
16 0.49 51 4.0 3.96 
17 0.50 51 4.0 3.83 
18 0.51 51 4.0 3.75 
19 0.49 49 4.1 2.04 
20 0.50 49 4.1 1.96 
21 0.51 49 4.1 1.95 
22 0.49 50 4.1 2.06 
23 0.50 50 4.1 1.96 
24 0.51 50 4.1 1.89 
25 0.49 51 4.1 2.05 
26 0.50 51 4.1 1.97 
27 0.51 51 4.1 1.91 
 32 
 36 
Table 8: Calculated effects for the different factors of the robustness test 33 
Factor Effect (± standard error*) 
Intercept 3.863 ± 0.01 
Flow (A) 
-0.161 ± 0.01 
Temperature (B) 
-0.054 ± 0.01 
pH (C) 
-5.248 ± 0.01 
AA 0.012 ± 0.02 
AB 
-0.002 ± 0.01 
AC 0.015 ± 0.01 
BB 0.020 ± 0.02 
BC 0.042 ± 0.01 
CC 1.454 ± 0.02 
 * standard errors are based on the total error with 17 degrees of freedom. 34 
 37 
Table 9: Analysis of variance for the resolution of the critical pair 35 




Mean square F-ratio P-values 
Flow (A) 0.11 1 0.12 239.34 < 0.00001 
Temperature 
(B) 
0.013 1 0.013 27.21 0.0001 
pH (C) 123.96 1 123.96 252839.53 < 0.00001 
AA < 0.001 1 < 0.001 0.49 0.4955 
AB < 0.001 1 < 0.001 0.03 0.8640 
AC < 0.001 1 < 0.001 1.38 0.2569 
BB < 0.001 1 < 0.001 1.27 0.2755 
BC < 0.001 1 < 0.001 10.62 0.0046 
CC 3.17 1 3.17 6465.5 < 0.00001 
Total error 0.008 17 < 0.001   
 36 
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